Featured news from NHIVNA
HIV-related news from NAM
Sofosbuvir demonstrates high response rate in interferon-free combination with ribavirin and GS-5555
Liz Highleyman, 2012-11-15 12:30:00
The hepatitis C polymerase inhibitor sofosbuvir produced high rates of sustained virological response in genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data presented this week at The Liver Meeting 2012, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.
The recent approval of the first direct-acting hepatitis C drugs has ushered in a new era of treatment, but many patients and providers eagerly await all-oral therapy that avoids interferon and its difficult side-effects. Several combinations of new direct-acting agents are now under study, but response rates remain suboptimal for the most difficult-to-treat patients.
Source:1
